Login
$AKBA
$0.47 +$0.02 (5.1%) After hours

$AKBA 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more

Date of Report (Date of earliest event reported): November 12, 2026

05 Nov 2026 8-K: Results of Operations and Financial Condition

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025

23 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the...

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company for personal reasons. His...

05 Aug 2026 8-K: Results of Operations and Financial Condition

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy

30 Jun 2026 8-K: Regulation FD Disclosure; Other Events

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Akebia Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the...

07 May 2026 8-K: Results of Operations and Financial Condition

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

01 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

CAMBRIDGE, Mass.—April 1, 2026—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader ...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues

30 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT (the “Agreement”) is entered into as of the 28th day of January, 2025 (the “Effective Date”), by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia” or the “Comp...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients

01 Dec 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio

17 Nov 2025 8-K: Entry into a Material Definitive Agreement

As previously disclosed, on May 24, 2023, Akebia Therapeutics, Inc. (the “Company”) and MEDICE Arzneimittel Putter GmbH & Co. KG (“Medice”) entered into a License Agreement (the “License Agreement”) pursuant to which the Company granted ...

10 Nov 2025 8-K: Results of Operations and Financial Condition

Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million

28 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA

07 Aug 2025 8-K: Results of Operations and Financial Condition

Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million

13 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, ret...

08 May 2025 8-K: Results of Operations and Financial Condition

Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025

20 Mar 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support